Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Further, AbbVie is collaborating on a coronavirus drug.

AbbVie Jumped Into The Coronavirus Drug Hunt — Is AbbVie Stock A Buy?

Eagle Bancorp Montana

H&R Block

Mackinac Financial

Virtu Financial

Bristol-Myers

Low-beta dividend paying names may be the best way to go in a volatile market.

6 Defensive Stocks to Beat the Volatility

Genmab - ADR

AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.

AbbVie Inks Deal With Genmab, Announces ADC Candidate Data

AbbVie scores in the courtroom, in the clinic, and in a collaboration deal.

3 Wins for AbbVie in 3 Days Provide 3 More Good Reasons to Buy the Pharma Stock

That's the finding of a clinical trial of ABBV-3373, a new type of antibody-drug conjugate.

AbbVie's Humira on Steroids (Literally) Treats Rheumatoid Arthritis Better Than the Original

The partners will develop and hopefully commercialize up to seven new cancer drugs.

AbbVie Signs $3.9 Billion Oncology Deal with Genmab

Shares of Genmab popped Wednesday after the biotech inked a deal with pharma giant AbbVie to develop cancer treatments. The deal is potentially worth billions in milestone payments.

Genmab Hits Pay Dirt On A Potential $3 Billion Deal With AbbVie

Fortinet

Eli Lilly

NVIDIA

Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.

ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks

NORTH CHICAGO, Ill., June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from a Phase 2a study of ABBV-3373, an investigational anti-tumor necrosis factor (TNF) Glucocorticoid Receptor Modulator (GRM) steroid...

Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis

Shares of Genmab A/S GMAB, +1.33% rose 4.5% in premarket trading Wednesday, after the Denmark-based biotechnology company announced a collaboration agreement with AbbVie Inc.

Genmab's stock surges after drug development deal with AbbView valued at up to nearly $4 billion

NORTH CHICAGO, Illinois and COPENHAGEN, Denmark, June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage...

AbbVie and Genmab Announce Broad Oncology Collaboration

Apple

Biogen

Disney

Intel

Microsoft

AT&T

Investors need to differentiate between speculative stocks rising higher than ever and proven blue-chip stocks, and stick to the latter.

7 of the Best Blue-Chip Stocks to Buy

AbbVie (ABBV) collaborates with three parties for developing an antibody-based treatment for COVID-19.

AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment

Broadcom

Cisco Systems

NextEra Energy

Tesla

Reopening of the economy and recently released better-than expected economic data strengthened investors' confidence in U.S. stocks.

4 Reasons Why Wall Street's V-Shaped Recovery Should Continue

Altria

Prudential Financial

W. P. Carey

It can be difficult for investors to find undervalued stock with the S&P 500 trading at a price-earnings multiple near 23.

Five Undervalued Stocks Yielding 5%

Aldeyra Therapeutics

Kezar Life Sciences Inc

Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma

NORTH CHICAGO, Ill., June 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new Phase 3 data from the SELECT-CHOICE clinical trial, showing that RINVOQ™ (upadacitinib, 15 mg, once daily) met the primary endpoint of...

AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients

AbbVie is jumping into the race for a coronavirus treatment, the pharmaceutical company said Friday as ABBV stock climbed higher. The company will focus on an antibody approach.

Pharma Giant AbbVie Enters Ring With A Potential Coronavirus Treatment

The biopharmaceutical giant is working with several partners on a monoclonal antibody treatment for the novel coronavirus.

AbbVie Enters the Race to Develop New COVID-19 Treatments

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass. and UTRECHT, Netherlands and ROTTERDAM, Netherlands and SUZHOU, China, June 5, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) today announced they have entered into a...

AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19

Acacia Communications

Amkor Technology

Calix

Hain Celestial Group

With Wall Street notching a 50-day rally amid signs of the economic slump bottoming out and history hinting further gains, investing in stocks that are poised to gain in the near term seems judicious.

50-Day Rally Spells Good Times for Wall Street: 5 Solid Buys

Bank of Montreal

Bank of Nova Scotia

MDU Resources Group

Philip Morris

5 High-Yield Blue-Chips I'm Buying For My Retirement Portfolio In This Overvalued Market

AbbVie (ABBV) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Increased Earnings Estimates Seen for AbbVie (ABBV): Can It Move Higher?

Analysts call ABBV stock a bargain after its $63 billion purchase of Allergan, whose existing drugs and pipeline are now expected to replace revenue from Humira.
The post Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk appeared first on InvestorPlace.

Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk

Interpublic Group of Companies

MetLife

People's United Financial

Unum

The market's violent rebound since the March 23 lows has been a welcome relief for long-term shareholders and a boon for dip buyers.

News for AbbVie Stock (ABBV)